

Distinct Roles of Estrogen Receptor- α and β in the Modulation of Vascular Inducible Nitric-Oxide Synthase in Diabetes

Andrea Cignarella, Chiara Bolego, Valeria Pelosi, Clara Meda, Andrée Krust, Christian Pinna, Rosa Maria Gaion, Elisabetta Vegeto, and Adriana Maggi

Department of Pharmacology and Anaesthesiology, University of Padova, Padova, Italy (A.C., C.B., V.P., R.M.G.); Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Disease, University of Milan, Milan, Italy (A.C., C.B., V.P., C.M., C.P., E.V., A.M.); and Institut de Genetique et de Biologie Moleculaire et Cellulaire, Institut Clinique de la Souris, Université Louis Pasteur de Strasbourg, Illkirch, France (A.K.)

Received July 14, 2008; accepted October 1, 2008

ABSTRACT

Estrogen is known to affect vascular function and diabetes development, but the relative contribution of estrogen receptor (ER) isoforms is unclear. The aim of this study was to determine how individual ER isoforms modulate inflammatory enzymes in the vascular wall of control and streptozotocin (STZ)-injected rodents. Primary cultures of rat aortic smooth muscle cells (SMCs) were stimulated with inflammatory agents in the presence or absence of increasing concentrations of the ER α and ER β -selective agonists 4,4',4''-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and diarylpropionitrile (DPN), respectively. The production of inducible nitric-oxide synthase (iNOS), a classical indicator of vascular inflammation, was significantly reduced by PPT in control but not diabetic SMCs, whereas it

was further enhanced by DPN treatment in both groups. This distinct action profile was not related to changes in ER transcriptional activity. However, extracellular signal-regulated kinase 1/2 signaling was activated by DPN but not by PPT in cytokine-treated SMCs. In cultured aortic rings from both normoglycemic and STZ-diabetic mice, pharmacological activation of ER α attenuated cytokine-driven iNOS induction by 30 to 50%. Vascular iNOS levels were decreased consistently when adding 1 nM 17 β -estradiol to aortic tissues from ER β - but not ER α -knockout mice. These findings suggest a possible role for ER α -selective ligands in reducing vascular inflammatory responses under normo- and hyperglycemic conditions.

Recent large-scale clinical trials found a significantly lower incidence of diabetes in postmenopausal women on hormone replacement therapy despite no improvement in vascular outcomes (Kanaya et al., 2003; Margolis et al., 2004). The mechanisms accounting for this outcome, however, are largely unknown, although estrogen is increasingly recognized as an important regulator of glucose homeostasis (Barros et al., 2006; Le May et al., 2006). Because the endogenous hormone binds to its receptors with identical affinity, the metabolic effects of individual estrogen receptor (ER) isoforms, ER α and ER β , are hard to differentiate and appear to be tissue- and species-specific. In accordance, there is little information as to how

ER α and ER β affect the course and timeline of diabetic vascular dysfunction, which ultimately results in macrovascular complications of clinical relevance. We previously demonstrated that anti-inflammatory activity of estrogen is impaired in vascular smooth muscle cells (SMCs) from streptozotocin (STZ)-diabetic rats, which display ER β overexpression with respect to normoglycemic controls (Maggi et al., 2003). The biological significance of ER β overexpression in vascular cells from diabetic rats is unclear. There have been concerns that ER β -selective agonists may be diabetogenic (Barros et al., 2006), whereas they are effective anti-inflammatory agents in selected *in vivo* models of inflammation (Harris, 2007).

Inducible nitric-oxide synthase (iNOS) is a well established marker of vascular inflammation (Bardell and MacLeod, 2001; Nagareddy et al., 2005). 17 β -Estradiol (E₂), a nonselective ER agonist, regulates iNOS protein expression via ER (Binko and Majewski, 1998; Zancan et al., 1999). In double ER-null mice,

This study was supported by the European Union Program EWA [Grant LSHM-CT-2005-518245]; by the National Institutes of Health [Grant R01-AG027713-01]; and by Italian Ministry of University and Research, Progetti di Ricerca de Interesse Nazionale [Grant 20006065483_003].

Article, publication date, and citation information can be found at <http://jpet.aspetjournals.org>.
doi:10.1124/jpet.108.143511.

ABBREVIATIONS: ER, estrogen receptor; SMC, smooth muscle cell; STZ, streptozotocin; iNOS, inducible nitric-oxide synthase; E₂, 17 β -estradiol; PPT, 4,4',4''-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol; DPN, diarylpropionitrile; ERK, extracellular signal-regulated kinase; PD98059, 2'-amino-3'-methoxyflavone; KO, knockout; FCS, fetal calf serum; M199, medium 199; ANOVA, analysis of variance; MEK, mitogen-activated protein kinase kinase.

iNOS expression in unstimulated aortic tissues is decreased as compared with wild-type mice (Liang et al., 2003). Data from our group indicate that moderately selective ER β agonists induce the expression of inflammatory enzymes, including iNOS, in rat vascular SMCs (Cignarella et al., 2006). Conversely, there is evidence that ER α mediates protective anti-inflammatory effects in vascular (Darblade et al., 2002; Ardelt et al., 2005) and nonvascular tissues (Vegeto et al., 2003; Ghisletti et al., 2005), including pancreatic β -cells (Le May et al., 2006). ER α -selective, but not ER β -selective, agonists improve vascular function by mediating vessel relaxation at concentrations where receptor selectivity is maintained (Bolego et al., 2005). Therefore, the role of ER isoforms in the modulation of vascular responses in settings of inflammation and diabetes is controversial. Based on this knowledge, we set out to assess the relative contribution of ER isoforms to vascular dysfunction in experimental insulin-deficient rodents using a comprehensive physiological and pharmacological approach.

Materials and Methods

Chemicals and Antibodies. E₂, lipopolysaccharide, and STZ were purchased from Sigma-Aldrich (St. Louis, MO); 4,4',4''-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT), diarylpropionitrile (DPN), and PD98059 were from Tocris Bioscience (Bristol, UK). The rabbit polyclonal anti-ERK antibody was from Santa Cruz Biotechnology, Inc., whereas the anti-iNOS antibody was from BD Biosciences (San Jose, CA). The peroxidase-coupled secondary antibody was obtained from Vector Laboratories (Burlingame, CA). Recombinant rat and mouse cytokines were obtained from Tebu-Bio (Magenta, Italy). Unless otherwise specified, chemicals were purchased from Merck (Darmstadt, Germany).

Animals. ER α - and ER β -KO mice have a C57B6 genetic background. Generation of these animals was described previously (Dupont et al., 2000). Male mice were used in the present study. Male Sprague-Dawley rats weighing 200 to 250 g (Charles River Italia, Calco, Italy) were kept in temperature-controlled facilities on a 12-h light/dark cycle and fed normal chow. At the time of cell or tissue harvest, animals were sacrificed by asphyxia using carbon dioxide. All procedures conformed to the *Guide for Care and Use of Laboratory Animals* (Institute of Laboratory Animal Resources, 1996).

Diabetes Induction. Diabetes was induced in 8-week-old wild-type or ER-KO mice littermates ($n = 32-35$) by a single intraperitoneal injection of 150 mg/kg STZ freshly dissolved in 50 mM citrate buffer, pH 4.5. In rats, STZ was given at 65 mg/kg i.p. Animals were diabetic for 3 weeks before aortic harvest and vascular cell isolation. Blood glucose was monitored after STZ injection using Glucurtest (Roche Diagnostics). Only animals with glycemia levels above 300 mg/dl on day 21 were used for experiments.

Cell Culture. SMCs obtained from aortic intimal-medial layers of Sprague-Dawley rats express ERs (Zancan et al., 1999; Maggi et al., 2003). These SMCs were isolated and cultured as described previously (Zancan et al., 1999; Maggi et al., 2003). In brief, SMCs at passage 6 were switched to phenol red-free M199 with 10% charcoal-stripped FCS for 2 days. Thereafter, they were synchronized in medium containing 0.4% FCS for 24 h and incubated for a further 24 h with a cytokine mixture comprising 10 ng/ml interleukin-1 β , 10 ng/ml interferon- γ , and 25 ng/ml tumor necrosis factor- α plus 1 μ g/ml lipopolysaccharide. Such a mixture consistently induces iNOS protein formation in SMCs (Zancan et al., 1999). ER agonists were added at the same time as cytokines.

Transient Transfections. For these experiments, 10⁵ SMCs were seeded in 24-well plates in minimal essential medium 199 without phenol red supplemented with 500 μ l/well 10% FCS and 50 U/ml penicillin G and 50 μ g/ml streptomycin sulfate. On the day of transfection, culture medium was replaced with Dulbecco's modified

Eagle's medium without phenol red supplemented with 10% FCS, 50 U/ml penicillin G, 50 μ g/ml streptomycin sulfate, 0.2 g/l glucose, and 20 mM L-glutamine. Transient transfections were performed using the reporter plasmid ERE-TATA_{luc} (0.8 μ g), in which luciferase expression is controlled by an estrogen-responsive element (from Dr. M. J. Tsai, Baylor College of Medicine, Houston, TX), in the absence or presence of pCMV-ER α or pCMV-ER β plasmids (0.02–0.2 μ g) coding for human ER α or ER β plasmids (from Dr. P. Chambon, Institut National de la Santé et de la Recherche Médicale, Illkirch, France). SMCs were transfected using the Lipofectamine reagents, according to the manufacturer's instructions (QIAGEN GmbH, Hilden, Germany). The day after transfection, culture medium was replaced with 500 μ l/well Dulbecco's modified Eagle's medium without phenol red supplemented with 1% FCS, and cells were incubated for 24 h before adding E₂. After 24 h, cells were rinsed once with PBS, and a protein extract was prepared and used to determine luciferase enzymatic activity as described previously (Ciana et al., 2001). Each experiment was performed on triplicate samples and repeated at least three times.

Tissue Culture. At sacrifice, the aorta was excised from the mice, carefully cleaned, transferred to ice-cold phosphate-buffered saline, and cut into 2-mm rings. Tissues from two mice were pooled and placed into a 30-mm culture dish containing phenol red-free M199 medium with 10% charcoal-stripped FCS for 2 days. At the end of this time, aortic tissues were stimulated with cytokines and treated with estrogenic compounds under conditions as described for cultured SMCs.

Western Blotting. Cultured SMCs or aortic tissues were washed twice with phosphate-buffered saline and extracted directly into lysis buffer as described elsewhere (Idel et al., 2002). Protein samples were pooled from at least six aortic rings isolated from three different animals. At least 30 μ g of cell protein were loaded onto 10% SDS-acrylamide gels. At the end of the run, proteins were transferred onto Hybond-ECL membranes (GE Healthcare, Chalfont St. Giles, UK). The membranes were incubated in blocking solution for 2 h and then incubated with primary antibodies (1:1000) overnight at room temperature. After washing, the peroxidase-conjugated secondary antibody (1:1000) was applied for 1 h at room temperature. After extensive washing, the blots were developed using an enhanced chemiluminescence kit (GE Healthcare). Sample loading control was performed through β -actin immunodetection.

Nitrite Assay. SMC culture medium was collected and centrifuged at 12,000 rpm for 5 min. Next, 250 μ l/well medium was treated with 20 μ l of 6.5 M HCl and 20 μ l of 37.5 mM sulfanilic acid in a 96-well plate. After incubation for 10 min, 20 μ l of 12.5 mM *N*-(1-naphthyl)-ethylenediamine was added. Optical density was read at 550 nm after 15 min. Nitrite values were expressed as micromoles of nitrite per milligram of cell protein.

Statistical Analysis. All data are presented as mean \pm S.E. and represent unpaired data. Cell culture data were obtained from at least four independent experiments, each value representing mean \pm S.E. of duplicate or triplicate determinations. Statistical evaluation was performed using unpaired Student's *t* test or one-way ANOVA with Fisher analysis when more than two groups were compared. Values of $P < 0.05$ were considered significant.

Results

Differential iNOS Modulation by ER-Selective Agonists in Cultured SMCs. With the aim to discern the role of individual ER isoforms in vascular inflammatory responses in control or hyperglycemic conditions, we used the isoform-selective ER agonists PPT and DPN (Bolego et al., 2006) at concentrations known to selectively activate ER α and ER β , respectively (Bolego et al., 2005, 2006; Harris, 2007). These compounds were first analyzed in primary culture of SMCs prepared from control or STZ-diabetic rat aortas and tested

for the ability to regulate the expression of iNOS, an established marker of vascular inflammation. Treatment with the ER α -selective agonist PPT significantly reduced cytokine-driven iNOS protein induction in aortic SMCs from control rats at 0.1 and 1 μ M (Fig. 1A), the maximal effect being a 30% reduction in iNOS levels. The negative regulation of iNOS expression after PPT incubation was not observed in aortic SMCs from STZ-diabetic rats (Fig. 1B). Consistent with this finding, PPT at the highest concentration tested reduced specific iNOS-mediated nitrite accumulation (Maggi et al., 2003) in the culture medium of SMCs from normoglycemic but not from STZ-diabetic rats (Fig. 1, C and D). These results are in agreement with previous data showing that E₂ blocks iNOS induction in aortic SMCs from control but not in those from STZ-diabetic rats, where nitrite production is reduced at baseline (Maggi et al., 2003). By contrast, the ER β -selective agonist DPN raised iNOS protein levels in both cytokine-treated control and diabetic SMCs (Fig. 2, A and B). This effect was concentration-dependent but was not associated with higher nitrite levels recovered in the culture medium (Fig. 2, C and D). PPT and DPN in the absence of cytomix did not induce either iNOS synthesis or NO release in cultured SMCs (data not shown). These results demon-

strate that ER α - and ER β -selective ligands differentially regulate iNOS production in vascular SMCs.

ER Signaling in Cultured SMCs. To explore whether the distinct action mediated by ER isoforms in diabetic SMCs could be ascribed to altered transcriptional activity, we transfected SMCs from control and diabetic animals with a reporter plasmid carrying the luciferase gene under the control of an estrogen-responsive promoter. E₂ activity could not be detected in SMCs transfected with the reporter plasmid alone (Fig. 3), suggesting that expression levels of endogenous ER isoforms might not be sufficient to induce detectable levels of reporter protein. Thus, we separately transfected either ER isoform and observed that both were transcriptionally active in a similar dose-dependent manner in SMCs from healthy and diseased animals, as shown in Fig. 3. It is interesting that the basal, unstimulated transcription activity of the two isoforms was higher in diabetic than in control SMCs. The experiment was repeated using different reporter/receptor ratios with superimposable results (data not shown). Thus, we conclude that diabetes did not impair ER transcriptional activity in SMCs. Therefore, we investigated whether ER isoforms could differentially affect the phosphorylation state of ERK1/2, an important component of cytokine recep-




Fig. 1. Effects of the ER α selective agonist PPT on iNOS expression in aortic SMCs. Cells were prepared from control (A and C) and STZ-diabetic (B and D) rats and then challenged with a cytokine mix for 24 h in the presence of vehicle or increasing concentrations of PPT. Cell lysates were tested for iNOS protein levels by Western blot (A and B). Graphs represent the scanning densitometry analysis whereby the intensity of the cytomix band was set arbitrarily to 1 (representative Western blots are shown). β -Actin was used as an internal control for sample loading. The culture media were harvested, and samples thereof were assayed for nitrite accumulation using the Griess reaction (C and D). Data are expressed as mean \pm S.E.M. of eight to 10 independent experiments. *, $P < 0.05$ compared with cytokines alone, ANOVA.




Fig. 2. Effects of the ER β -selective agonist DPN on iNOS expression in aortic SMCs. Cells were prepared from control (A and C) and STZ-diabetic (B and D) rats and then challenged with a cytokine mix in the presence of vehicle or increasing concentrations of DPN. Western blot analysis and high-output NO release assays were performed as described in the legend to Fig. 1. Data are expressed as mean \pm S.E.M. of eight to 10 independent experiments. *, $P < 0.05$ compared with cytokines alone, ANOVA.

tor intracellular signaling linked to vascular inflammation (Siow et al., 2007). Whereas PPT had no effect on this pathway under the same conditions as those showing iNOS inhibition (Fig. 4, A and B), a significant increase in the amount of phosphorylated ERK1/2 was observed in control SMCs after DPN treatment ($P < 0.05$; Fig. 4C), and this effect was abolished by the specific MEK-1 inhibitor PD98059. On the other hand, ERK activation was not enhanced by DPN in SMCs from STZ-diabetic rats (Fig. 4D), possibly because of overactivation of ERK1/2 as compared with the nondiabetic state. Total ERK1/2 levels were unchanged in these experiments (data not shown). These results suggest that ER β activation is linked to the induction of the specific signaling pathway in SMCs.

Pharmacological Activation of ER Isoforms and iNOS Expression in Aortic Rings from Wild-Type Mice. We next determined to what extent selective ER activation affected cytokine-driven iNOS production in a model system more reminiscent of the physiological setting, namely tissue cultures of aortic sections freshly isolated from mice 3 weeks after injection of STZ or vehicle. Tissues were incubated with a mixture of inflammatory cytokines in the presence or absence of ER agonists (Kauser et al., 1998). The iNOS protein was not detectable by Western analysis in untreated aortic rings (data not shown). Consistent with the above isolated SMC findings, coadministration of 1 nM E₂ and cytokines significantly reduced iNOS

levels in tissues from normoglycemic mice stimulated with cytokines ($n = 5$; Fig. 5A). The ER α -selective agonist PPT essentially mimicked E₂ action, whereas treatment with the ER β -selective agonist DPN tended to increase arterial iNOS expression, although this effect did not reach statistical significance ($n = 4$; Fig. 5A). It is interesting that this regulatory profile was retained in aortic rings from STZ-diabetic mice ($n = 4$; Fig. 5B), where E₂ and PPT reduced iNOS induction, whereas ER β activation again resulted in a trend to increasing iNOS production ($n = 4$, Fig. 5B). These data support the relevance of ER-selective agents in the pharmacological control of vascular iNOS under both physiologic and hyperglycemic conditions.

Physiological Relevance of ER Isoforms on Glycemic Control and Vascular iNOS Expression in Control and STZ-Injected Mice. To conclusively demonstrate that ER α and ER β mediate distinct actions in the aorta, we used ER α or ER β gene-deleted (KO) mice (Dupont et al., 2000) and assessed the effect of E₂ on vascular iNOS levels in aortic tissues normoglycemic and STZ-diabetic mice. Preliminary characterization of the effects of ER gene ablation on glucose homeostasis was performed by measuring baseline fasting glucose levels. In fasted animals, circulating glucose levels were significantly higher in ER α -KO than in wild-type or ER β -KO mice (Fig. 6A), in agreement with previous studies (Le May et al., 2006). Despite this difference at baseline,




Fig. 3. Transcriptional activity of ER isoforms in aortic SMCs. Cells were transfected with increasing concentrations of ER α and ER β and treated with 1 nM E₂ for 24 h. The ERE-TATA-luc activity was measured as relative luciferase units (RLUs). Data are expressed as mean \pm S.E.M. of three independent experiments performed in triplicate. All E₂ samples were significantly different from vehicle samples ($P < 0.05$); all diabetes samples were significantly different from the corresponding control samples ($P < 0.05$) except nontransfected samples (N.S.).

glycemic levels after STZ injection tended to be higher in ER α -KO and ER β -KO as compared with wild-type mice (Fig. 6B), yet blood glucose did not differ significantly among groups after 3 weeks at sacrifice. We also noticed ER β deletion predisposed to STZ toxicity as shown by the lower cumulative survival rate compared with ER α -KO and wild-type mice (data not shown).



We next prepared aortic ring cultures from these mice groups and evaluated iNOS production after cytokine treatment in the absence or presence of 10^{-9} M E₂. In healthy animals lacking ER α , E₂ increased cytokine-driven iNOS protein accumulation (Fig. 7A), whereas it significantly reduced iNOS protein content in ER β -KO mice ($n = 3-4$; Fig. 7C). Consistent with ER-selective agonist data, these results indicate that ER α mediates the inhibitory activity of E₂ on inflammatory markers in the intact vessel wall, whereas ER β is associated with opposite effects. It is interesting that in STZ-treated ER β -KO mice, E₂ treatment still resulted in a significant reduction in iNOS accumulation ($n = 3-5$; Fig. 7D), demonstrating a prominent role of ER α in vascular inflammation also in insulin-deficient mice. E₂ unexpectedly did not modify iNOS induction upon ER α ablation (Fig. 7B), showing that selective activation of ER β by E₂ did not correlate with increased iNOS stimulation. Based on these findings, we conclude that ER α , but not ER β , is involved in the

protective effects of E₂ on the inflammatory response of the vessel wall in normoglycemic and STZ-diabetic rodents.

Discussion

In the present study, combined application of specific pharmacologic and genetic tools provides novel insights into beneficial effects of ER α -selective agonists in specific aspects of vascular inflammation associated with diabetes. The first finding of our study is the direct demonstration that ER α reduces, whereas ER β increases, cytokine-driven iNOS induction in vascular cells and, most importantly, that ER α anti-inflammatory activity is retained in the arterial wall of diabetic mice. This leads to the second relevant observation of our study that ER α -selective agonists inhibit specific aspects of vascular inflammation under both control and diabetic conditions. Because this effect was observed in whole aortic rings but not in isolated SMCs from diabetic animals, ER α activation requires the more physiological yet complex context of the vascular tissue, comprising the endothelium, SMCs, and adventitial cells, to blunt inflammatory enzyme action. Of note, the transcriptional machinery of both ER isoforms in response to E₂ was not impaired in SMCs from diabetic rats (Fig. 3). In line with our findings, previous studies showed the selective involvement of ER α in glucose uptake in the skeletal muscle and pancreas (Barros et al., 2006; Le May et al., 2006) and in reducing iNOS expression in endothelium-denuded aortic rings (Zhu et al., 2002). Whether ER α function is affected by macrovascular complications developing at more advanced stages of diabetes remains to be investigated. As to the specific involvement of ER β activation, our study provides indication but no clear-cut evidence for a proinflammatory action in the arterial wall. For instance, DPN effects on cytokine-induced iNOS levels in mouse aorta only approached statistical significance; similarly, E₂ did not affect cytokine activity in aortic rings from STZ-injected ER α -KO mice (Fig. 7B). These data suggests that the mechanism of action of ER β in vivo, particularly in diabetes, is more complex and needs further investigation. It should be noted that ERs may also control NO-related pathways by modulating either the expression of iNOS monomer, which is without enzymatic activity, or the production of enzymes other than iNOS. For instance, arginase is increased in diabetic blood vessels, and the deficit in NO is normalized by adding an arginase inhibitor (Romero et al., 2008). Because estrogens positively regulate arginase expression and activity in nonvascular tissues (Traish et al., 2003), some of our results on NO production could be interpreted by differences in ER α - versus ER β -mediated differences in arginase expression.

A further contribution of this work is the partial definition of isoform-specific mechanisms that appear to be affected differentially and distinctly in vascular cells. Our present observation that ER β , but not ER α , affected the phosphorylation state of ERK1/2, at least in nondiabetic SMCs, suggests that the signaling of the two receptor isoforms is diversified, leading to distinct profiles of intracellular actions in vascular wall cells (Fig. 8). In fact, induction of the ERK1/2 pathway may lead to transcriptional activation of target genes such as iNOS (Siow et al., 2007). Although the link between ER control of iNOS induction and the mitogen-activated protein kinase pathway is not definitely proven, the






Fig. 6. Blood glucose levels in wild-type, ER α -KO, and ER β -KO mice. Fasting blood glucose levels were evaluated in control animals (A; $n = 17$) or as a time course assay of random-fed blood glucose (B) in wild-type, ER α -KO, and ER β -KO mice after streptozotocin injection. *, $P < 0.01$ versus wild-type and ER β -KO, one-way ANOVA.




Fig. 7. Western blot analysis of iNOS in aortic tissues from ER-KO mice. Aortic rings were from control (A and C) and STZ-diabetic (B and D) mice with an ER α -KO (A and B) or ER β -KO (C and D) genotype. Tissue cultures were challenged with a cytokine mix as described in the legend to Fig. 1 in the presence of 1 nM E₂ or its vehicle ($n = 3$ to 5). Graphs represent the scanning densitometry analysis whereby the intensity of the cytomix band in each animal group was set arbitrarily to 1. Representative Western blots are shown. *, $P < 0.05$ versus cytokines alone, ANOVA.

mitogen-activated protein kinase system is sensitive to ER-specific regulation, as previously demonstrated in mouse microglia (Baker et al., 2004) and vascular cells (Haas et al.,

2007), and may be involved in cytokine-driven iNOS activation. Preliminary data (data not shown) suggest that ER signaling affects additional pathways related to iNOS induc-




Fig. 8. Proposed scheme of differential ER action on iNOS expression in the vascular wall. ER α activation negatively regulates cytokine-driven iNOS accumulation in aortic tissues from normo- (A) and hyperglycemic (B) rodents. By contrast, ER β activation increases iNOS levels. This may occur through induction of MEK-1-dependent phosphorylated ERK 1/2 generation in tissues from normoglycemic rodents (A). ER β activation may increase iNOS levels also through enhanced cytokine signaling via phosphorylated ERK 1/2, which is generally overactivated in diabetes (B). Thick arrows, enhanced pathways; dashed arrows, general regulatory pathways of iNOS expression.

tion in vascular SMCs. To our knowledge, this is the first study demonstrating that in a given cell ER β , but not ER α , may differentially interact with cytoplasmic or nuclear proteins. The identification of molecular mechanisms of ER activity on vascular inflammation holds promise for improving our understanding of estrogen action in the vasculature.

Further implications of the present work arise from the distinct role of ER α and ER β in regulating vascular function because an imbalance in ER α versus ER β pathways may predispose to vascular dysfunction and complications (Barros et al., 2006). In fact, ER expression profile has been shown to vary in association with physiologic or pathologic conditions including hypoestrogenicity and inflammation (Lindner et al., 1998; Marriott et al., 2007; Pinna et al., 2008). Because ER activity is strictly dependent upon the interaction with coregulators and enzymes (Harrington et al., 2003), alterations in expression or activity of these intracellular partners might impinge on receptor activity as well. Thus, it is reasonable that alterations in the ratio or activity of ER isoforms affect the outcome of estrogen action. In addition, an unfavorable ER α /ER β ratio may foster heterodimerization between the two isoforms (Pettersson et al., 1997), hindering ER α protective activity. Our data are in agreement with a recent study showing opposing functions for ER α and ER β in regulating distinct sets of genes in the mouse aorta in response to E₂ (O'Lone et al., 2007). Although the observed effects on iNOS protein may not be reflective of inflammatory effects overall, the present findings support our hypothesis that ER-selective ligands represent safer compounds for the vessel wall integrity with respect to currently used nonselective hormone agents (Bolego et al., 2006).

This and other studies point to an emerging role for ERs as regulators of glucose homeostasis and metabolic disease (Barros et al., 2006; Bryzgalova et al., 2006; Deroo and Korach, 2006; Le May et al., 2006). Over the last few years, several reports disclosed the relevance to glucose metabolism and insulin sensitivity of other members of the nuclear receptor superfamily, including liver X receptor and farnesoid X receptor (Cao et al., 2003; Laffitte et al., 2003; Zhang et al., 2006). Although adding to the well established role of PPARs in the field, these observations raise the question of whether

molecular pathways shared by activated nuclear receptors (if any) govern the integrated coordination of lipid and glucose metabolism. Candidate pathways or targets may be identified eventually that are amenable to developing novel solutions in drug discovery.

From a pharmacological perspective, the finding that a selective ER α agonist, avoiding ER β activation, preserves its anti-inflammatory action even in the presence of persistent hyperglycemia highlights potential benefits of isoform-selective ER ligands. In fact, the nonselective ER agonist E₂ may trigger conflicting effects in those tissues where ER α and ER β are coexpressed, thereby outweighing potential therapeutic benefits mediated by either isoform. The availability of isoform-selective ER compounds thus represents a powerful investigational tool that will help unravel the details of ER α and ER β interactions among each other and with other cellular components in the vasculature and, hopefully, will enable us to exploit potential therapeutic action of ER agonists, particularly in the therapy of disorders associated with the postmenopause.

Acknowledgments

We thank Pierre Chambon for helpful discussion and Monica Rebecchi, Sabrina Etteri, Samanta Oldoni, and Paolo Sparaciarri for precious work.

References

- Ardelt AA, McCullough LD, Korach KS, Wang MM, Munzenmaier DH, and Hurn PD (2005) Estradiol regulates angiopoietin-1 mRNA expression through estrogen receptor- α in a rodent experimental stroke model. *Stroke* **36**:337–341.
- Baker AE, Brautigam VM, and Watters JJ (2004) Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor β . *Endocrinology* **145**:5021–5032.
- Bardell AL and MacLeod KM (2001) Evidence for inducible nitric-oxide synthase expression and activity in vascular smooth muscle of streptozotocin-diabetic rats. *J Pharmacol Exp Ther* **296**:252–259.
- Barros RP, Machado UF, and Gustafsson JA (2006) Estrogen receptors: new players in diabetes mellitus. *Trends Mol Med* **12**:425–431.
- Barros RP, Machado UF, Warner M, and Gustafsson JA (2006) Muscle GLUT4 regulation by estrogen receptors ER β and ER α . *Proc Natl Acad Sci U S A* **103**:1605–1608.
- Binko J and Majewski H (1998) 17 β -estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. *Am J Physiol* **274**:H853–H859.
- Bolego C, Cignarella A, Sanvito P, Pelosi V, Pellegatta F, Puglisi L, and Pinna C (2005) The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor- α agonists and is abolished by estrogen deprivation. *J Pharmacol Exp Ther* **313**:1203–1208.
- Bolego C, Vegeto E, Pinna C, Maggi A, and Cignarella A (2006) Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. *Arterioscler Thromb Vasc Biol* **26**:2192–2199.
- Bryzgalova G, Gao H, Ahren B, Zierath JR, Galuska D, Steiler TL, Dahlman-Wright K, Nilsson S, Gustafsson JA, Efendic S, et al. (2006) Evidence that oestrogen receptor- α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. *Diabetologia* **49**:588–597.
- Cao G, Liang Y, Broderick CL, Oldham BA, Beyer TP, Schmidt RJ, Zhang Y, Staybrook KR, Suen C, Otto KA, et al. (2003) Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. *J Biol Chem* **278**:1131–1136.
- Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiverson C, and Maggi A (2001) Engineering of a mouse for the in vivo profiling of estrogen receptor activity. *Mol Endocrinol* **15**:1104–1113.
- Cignarella A, Minici C, Bolego C, Pinna C, Sanvito P, Gaion RM, and Puglisi L (2006) Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. *Nutr Metab Cardiovasc Dis* **16**:322–329.
- Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, Chambon P, Bayard F, and Arnal JF (2002) Estradiol alters nitric oxide production in the mouse aorta through the α -, but not β -, estrogen receptor. *Circ Res* **90**:413–419.
- Deroo BJ and Korach KS (2006) Estrogen receptors and human disease. *J Clin Invest* **116**:561–570.
- Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, and Mark M (2000) Effect of single and compound knockouts of estrogen receptors α (ER α) and β (ER β) on mouse reproductive phenotypes. *Development* **127**:4277–4291.
- Ghisletti S, Meda C, Maggi A, and Vegeto E (2005) 17 β -estradiol inhibits inflammatory gene expression by controlling NF- κ B intracellular localization. *Mol Cell Biol* **25**:2957–2968.
- Haas E, Meyer MR, Schurr U, Bhattacharya I, Minotti R, Nguyen HH, Heigl A, Lachat M, Genoni M, and Barton M (2007) Differential effects of 17 β -estradiol on function and expression of estrogen receptor α , estrogen receptor β , and GPR30 in arteries and veins of patients with atherosclerosis. *Hypertension* **49**:1358–1363.

- Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, and Katzenellenbogen BS (2003) Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. *Mol Cell Endocrinol* **206**:13–22.
- Harris HA (2007) Estrogen receptor- β : recent lessons from in vivo studies. *Mol Endocrinol* **21**:1–13.
- Idel S, Ellinghaus P, Wolfrum C, Nofer JR, Gloerich J, Assmann G, Spener F, and Seedorf U (2002) Branched chain fatty acids induce nitric oxide-dependent apoptosis in vascular smooth muscle cells. *J Biol Chem* **277**:49319–49325.
- Institute of Laboratory Animal Resources (1996) *Guide for the Care and Use of Laboratory Animals*, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
- Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E; Heart and Estrogen/progestin Replacement Study (2003) Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* **138**:1–9.
- Kausar K, Sonnenberg D, Diel P, and Rubanyi GM (1998) Effect of 17 β -oestradiol on cytokine-induced nitric oxide production in rat isolated aorta. *Br J Pharmacol* **123**:1089–1096.
- Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, et al. (2003) Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. *Proc Natl Acad Sci U S A* **100**:5419–5424.
- Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, and Mauvais-Jarvis F (2006) Estrogens protect pancreatic β -cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. *Proc Natl Acad Sci U S A* **103**:9232–9237.
- Liang M, Ekblad E, Lydrup ML, and Nilsson BO (2003) Combined lack of estrogen receptors α and β affects vascular iNOS protein expression. *Cell Tissue Res* **313**:63–70.
- Lindner V, Kim SK, Karas RH, Kuiper GG, Gustafsson JA, and Mendelsohn ME (1998) Increased expression of estrogen receptor- β mRNA in male blood vessels after vascular injury. *Circ Res* **83**:224–229.
- Maggi A, Cignarella A, Brusadelli A, Bolego C, Pinna C, and Puglisi L (2003) Diabetes undermines estrogen control of inducible nitric oxide synthase function in rat aortic smooth muscle cells through overexpression of estrogen receptor- β . *Circulation* **108**:211–217.
- Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, and Howard BV; Women's Health Initiative Investigators (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. *Diabetologia* **47**:1175–1187.
- Marriott LK, McGann-Gramling KR, Hauss-Wegrzyniak B, Sheldahl LC, Shapiro RA, Dorsa DM, and Wenk GL (2007) Brain infusion of lipopolysaccharide increases uterine growth as a function of estrogen replacement regimen: suppression of uterine estrogen receptor- α by constant, but not pulsed, estrogen replacement. *Endocrinology* **148**:232–240.
- Nagareddy PR, Xia Z, McNeill JH, and MacLeod KM (2005) Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. *Am J Physiol Heart Circ Physiol* **289**:H2144–H2152.
- O'Lone R, Knorr K, Jaffe IZ, Schaffer ME, Martini PG, Karas RH, Bienkowska J, Mendelsohn ME, and Hansen U (2007) Estrogen receptors α and β mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. *Mol Endocrinol* **21**:1281–1296.
- Pettersson K, Grandien K, Kuiper GG, and Gustafsson JA (1997) Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α . *Mol Endocrinol* **11**:1486–1496.
- Pinna C, Cignarella A, Sanvito P, Pelosi V, and Bolego C (2008) Prolonged ovarian hormone deprivation impairs the protective vascular actions of estrogen receptor α agonists. *Hypertension* **51**:1210–1217.
- Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M, Caldwell RB, and Caldwell RW (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. *Circ Res* **102**:95–102.
- Siow RC, Li FY, Rowlands DJ, de Winter P, and Mann GE (2007) Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes. *Free Radic Biol Med* **42**:909–925.
- Traish AM, Kim NN, Huang YH, Min K, Munarriz R, and Goldstein I (2003) Sex steroid hormones differentially regulate nitric oxide synthase and arginase activities in the proximal and distal rabbit vagina. *Int J Impot Res* **15**:397–404.
- Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, Ciana P, Chambon P, et al. (2003) Estrogen receptor- α mediates the brain antiinflammatory activity of estradiol. *Proc Natl Acad Sci U S A* **100**:9614–9619.
- Zancan V, Santagati S, Bolego C, Vegeto E, Maggi A, and Puglisi L (1999) 17 β -estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. *Endocrinology* **140**:2004–2009.
- Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, and Edwards PA (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. *Proc Natl Acad Sci U S A* **103**:1006–1011.
- Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgins J, Shaul PW, Thoren P, Smithies O, et al. (2002) Abnormal vascular function and hypertension in mice deficient in estrogen receptor β . *Science* **295**:505–508.

Address correspondence to: Adriana Maggi, Center of Excellence on Neurodegenerative Disease, University of Milan, Via Balzaretto 9, 20133 Milan, Italy. E-mail: adriana.maggi@unimi.it
